Original Publication Date: 1 May, 2015
Publication / Source: Future Oncology
Authors: Simon J Johnston & Kwok-Leung Cheung
A Cochrane review of randomized trials shows no difference in overall survival between surgery and primary endocrine therapy (PET) in older women with operable primary breast cancer. Most of these trials were small and unselected for estrogen receptor (ER) status. Evidence exists showing a significant correlation between the degree of ER-positivity and response and outcome in patients receiving PET.
To view restricted content, please:
